On October 30, 2026, a large expiry of 322,586 Ethereum options valued at approximately $777 million will occur on the Deribit exchange. This represents over 21% of all open ETH contracts there, with a significant concentration of call options at the $2,600 strike price, indicating a bet on price recovery. The max pain price, where option holders lose the most, is calculated at $2,500, but this is not a forecast. Price volatility is expected as sellers hedge their positions, especially within the $2,300 to $2,600 range. Meanwhile, the spot price has remained below $2,500 for eleven days, suggesting cautious market sentiment. Investors with leverage should be mindful of liquidation risks near these levels. The expiry is a key event for price direction but does not guarantee a price move to the strike prices.
The Ethereum options expiry on October 30, 2026, is a notable event in the crypto market. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 01:31 WIB: out of 50 major cryptocurrencies, 43 rose and 6 fell today. Among movers, COTI rose 5.87% to Rp205 with 84% sell orders, VET increased 4.79% to Rp132 with 88% sell orders, and BCH gained 4.58% to Rp5,148,451 with a more balanced 56% sell and 44% buy orders. Typical hold times range from 69 to 148 days across these assets.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
